Insulin Maker Learns Brutal Lesson: Sometimes Innovation Doesn't Pay

For almost a century, Novo Nordisk rolled out new versions of its core product at higher prices. Then suddenly, customers including governments and insurers decided the older, less expensive versions were good enough.

from WSJ.com: US Business http://ift.tt/2fIWwUd
via IFTTT